CD274 and head and neck squamous cell carcinoma: On the other hand, the anti-PD-L1 antibody durvalumab has been evaluated in a phase II study in 111 patients with platinum pre-treated HNSCC; a high PD-L1 expression level of ≥ 25% was required for inclusion in the study (116).